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Abstract: Fatigue and muscle wasting are common symptoms experienced 
by cancer patients. Data from animal models demonstrate that angiotensin is 
involved in tumor-induced muscle wasting, and that tumor growth can 
independently affect myocardial function, which could contribute to fatigue in 
cancer patients. In clinical studies, inhibitors of angiotensin converting 
enzyme (ACE) can prevent the development of chemotherapy-induced 
cardiovascular dysfunction, suggesting a mechanistic role for the renin-
angiotensin-aldosterone system (RAAS). In the present study, we 
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investigated whether an angiotensin (AT)1-receptor antagonist could prevent 
the development of tumor-associated myocardial dysfunction. Methods and 
Results: Colon26 adenocarcinoma (c26) cells were implanted into female 
CD2F1 mice at 8 weeks of age. Simultaneously, mice were administered 
Losartan (10 mg/kg) daily via their drinking water. In vivo echocardiography, 
blood pressure, in vitro cardiomyocyte function, cell proliferation assays, and 
measures of systemic inflammation and myocardial protein degradation were 
performed 19 days following tumor cell injection. Losartan treatment 
prevented tumor-induced loss of muscle mass and in vitro c26 cell 
proliferation, decreased tumor weight, and attenuated myocardial expression 
of interleukin-6. Furthermore, Losartan treatment mitigated tumor-associated 
alterations in calcium signaling in cardiomyocytes, which was associated with 
improved myocyte contraction velocity, systolic function, and blood pressures 
in the hearts of tumor-bearing mice. Conclusions: These data suggest that 
Losartan may mitigate tumor-induced myocardial dysfunction and 
inflammation. 
Keywords: cancer cachexia, cardiovascular function, calcium signaling, 
Losartan, cardiomyocyte 
Introduction 
Cancer cachexia, a syndrome consisting of fatigue, muscle 
wasting, and weight loss with or without anorexia, is observed in a 
large percentage of cancer patients with incurable disease1 and 
contributes to 22 percent of cancer deaths.1,2 New research by our lab 
and others has shown that cancer cachexia involves not only the loss 
of skeletal muscle, but can also cause pathologic alterations within the 
heart.2,3 The resultant effects on myocardial function likely contribute 
to fatigue and decreased quality of life in these patients. 
We and others have demonstrated tumor-induced cardiac 
remodeling and myocardial dysfunction.2–4 Tumor-induced cardiac 
remodeling involves increased expression of pro-inflammatory 
cytokines, such as interleukin-6 (IL-6).5 as well as ventricular wall 
thinning and decreased troponin I levels (a protein involved in cardiac 
contraction).2 Previous work from our lab has also shown increased 
expression of MAFbx mRNA, a muscle-specific ubiquitin ligase involved 
in the ubiquitin proteasome pathway (UPP) of protein degradation, and 
Bnip3, a protein involved in the formation of autophagic vesicles, in 
mouse hearts inoculated with the colon26 (c26) adenocarcinoma cell 
line [3]. We also recently showed that IL-6 levels are elevated in both 
the serum and heart muscle in this model.3 Together, these results 
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indicate an increase in muscle protein degradation and inflammation in 
the heart, and myocardial dysfunction due to growth of the c26 
adenocarcinoma. 
Current data regarding the impact of the renin-angiotensin-
aldosterone system (RAAS) on the development of cancer-induced 
myocardial dysfunction and its potential therapeutic properties are 
inconclusive. Angiotensin II receptor subtypes 1 and 2 (AT1 and 2) 
have direct effects on tumor development through the induction of cell 
proliferation and vascular endothelial growth factor (VEGF)-induced 
angiogenesis.6 Furthermore, the AT2 receptor antagonist Losartan has 
been shown to limit tumor-associated angiogenesis, inhibit collagen 
synthesis, and attenuate tumor progression. Additionally, Losartan 
improves the distribution and efficacy of nanotherapeutics in tumor 
therapy.7 Recently, a clinical trial revealed that treatment with a high 
dose of the ACE inhibitor Enalapril and also beta-receptor blocker 
treatment with Carvedilol prevented the development of 
chemotherapeutic-induced myocardial dysfunction.8 These studies 
suggest a mechanistic role for the RAAS in cancer treatment-induced 
myocardial dysfunction.9 Experimental studies reported preventative 
effects of beta-blockers and aldosterone antagonists but not 
angiotensin-converting-enzyme (ACE) inhibitors on loss of body weight 
and skeletal muscle mass, as well as tumor-induced alterations in 
cardiac dimensions in a mouse model of liver cancer-induced cardiac 
cachexia and muscle wasting.10 More recent studies indicated that 
combined treatments of chemotherapeutics with AT1 receptor 
antagonists improved survival.11 However, few studies have 
investigated the role of the RAAS in the direct effects of tumor 
progression and subsequent myocardial dysfunction and potential 
therapeutic prospects. 
The RAAS is known to play a major role in myocardial 
remodeling and dysfunction. Recently, Angiotensin II (AngII) has been 
implicated in skeletal muscle catabolism in tumor-bearing animals via 
activation of the UPP of myosin protein degradation. These data 
suggest that the RAAS could play a role in tumor-induced myocardial 
dysfunction.12–17 In order to examine the impact of the RAAS in tumor-
induced myocardial dysfunction and potential therapeutic feasibility, 
we treated c26 tumor-bearing mice with Losartan (LOS), an AT1 
antagonist, and examined in vivo and in vitro myocardial function, 
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blood pressures, and AngII serum concentration following cancer 
cachexia development. 
Materials and Methods 
Animal Model 
Animal protocols were approved by the Institutional Care and 
Use Committee (IACUC) at the Research Institute at Nationwide 
Children’s Hospital and The Ohio State University. One hundred adult 
(8 week old) female CD2F1 mice (Harlan) were handled in accordance 
with NIH guidelines and housed in a specific pathogen free facility, five 
per cage on a 12 hour light/dark cycle. Half of the mice were 
inoculated with c26 tumor cells (tumor) and half injected with a similar 
saline volume served as healthy controls (control). The c26 cells were 
cultured and injected subcutaneously above the scapula, as previously 
described.3 Half of the tumor (tumor/LOS) and half of the control 
(control/LOS) mice were administered 10 mg/kg of Losartan (LOS) 
daily via their drinking water, beginning on the day of tumor cell 
injection. 
Animals were euthanized on day 19 after tumor cell injection via 
pentobarbital injection (20mg/kg for myocyte isolation) or carbon 
dioxide inhalation followed by cervical dislocation for tissue collection 
as approved by the American Veterinary Medicine Association Panel on 
Euthanasia. Hearts were removed, weighed and then used for primary 
cardiomyocyte isolation or snap-frozen in liquid nitrogen for molecular 
analyses. Gastrocnemius muscles and tumors were removed, weighed, 
and snap-frozen in liquid nitrogen. 
Real-time Polymerase Chain Reaction 
Total RNA was extracted from 100 mg cardiac tissue as 
previously described.3 Real time PCR (RT-PCR) for MAFbx (Forward 5′-
GTGCTTACAACTGAACATATGCA-3′; Reverse 5′-TGGCCCAGGCTGACCA-
3′), GAPDH (Forward 5′-ATGGTCAAGGTCGGTGTGAACGG-3′; Reverse 
5′-AGGGGTGGTTGATGGCAACAATCT-3′) and IL-6 (Forward 5′-
GCCAGAGTCCTTCAGAGAGATACAGAAACTC-3′; Reverse 5′-
AGCCACTCCTTCTGTGACTCCAGCTTA-3′) was performed using primer 
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pairs and SYBR super mix (BioRad). The TaqMan Gene Expression 
Assay was used to detect gene expression of Bnip3 according to the 
manufacturer’s instructions. Briefly, 25 μl samples were run in 
duplicate in an iCycler iQ5 (BioRad) for 40 cycles at 95°C for 15 
seconds and 60°C for 1 minute after the initial 10 minute 95°C 
denaturation period. MAFbx, Bnip3, and IL-6 levels were all normalized 
to GAPDH expression.3 
Plasma Cytokines 
Plasma was obtained from mice using an abdominal aortic stick 
immediately following euthanasia. Blood was collected in EDTA tubes 
and centrifuged at 1500 x g, 10 min, 4°C to separate the plasma. 
Plasma levels of interleukin (IL)-1, IL-6, IL-10, IL-12, interferon-
gamma (IFN-γ), tumor necrosis factor-α (TNF-α), and chemokine (C-
X-C motif) ligand 1 (CXCL1) were measured using the MSD Mouse Pro-
inflammatory 7-Plex Ultra-Sensitive Kit (Meso Scale Discovery 
K15012C) according to the manufacturer’s instructions. 
Echocardiography 
On day 19 post-injection, in vivo cardiac function was assessed 
in 56 mice (15 control, 14 control/LOS, 17 tumor, and 10 tumor/LOS) 
via echocardiography using a VisualSonics Vevo 2100 Ultra High 
Resolution In Vivo Imaging System (VisualSonics, Toronto, ON, 
Canada) as previously described.3,18 Briefly, mice were anesthetized 
with 1.5% isofluorane in an anesthesia induction chamber. Following 
the induction of anesthesia, mice were placed on a warming pad, and 
connected to a three lead electrocardiogram monitor. During 
echocardiographic analyses, mice were continuously sedated with 
1.0% isoflurane (in 100% O2) to receive identical anesthetic conditions 
for all groups. Left ventricular systolic diameter (LVESd), left 
ventricular diastolic diameter (LVEDd) and left ventricular posterior wall 
thickness at systole (PWTs) and diastole (PWTd) were measured using 
the M-mode echocardiogram. Fractional shortening (FS) was calculated 
using FS=(LVEDd-LVESd)/LVEDd*100. Ejection fraction (EF) was 
calculated using the following equation: EF=(LVEDd-
LVESd/LVEDd)*100. Stroke volume (SV) was calculated using the 
Doppler flow Velocity-Time Integral (VTI) at the LV outflow tract 
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(LVOT) and the aortic diameter (Ao), (LVOT2 * 0.785 * Ao VTI). LV 
mass was calculated using the equation (left ventricular anterior wall 
(LVAW)+LVEDd+ PWTd)3-(LVEDd)3.19 
Ventricular Myocyte Isolation and Functional 
Assessment 
Following echocardiography, cardiomyocytes were isolated as 
previously described3,18,20–23 Briefly, the hearts were removed and 
retrograde perfusion was performed with buffer, followed by 0.25 
mg/ml Liberase DH (Roche), 0.14 mg/ml 2.5% Trypsin (Gibco) and 
12.5 μM CaCl2 for 5–7 minutes. Cells were dissociated by repeated 
pipetting and then filtered to remove cellular debris. Cardiomyocytes 
were exposed to increasing concentrations of CaCl2 (to minimize the 
calcium paradox) and then plated on laminin-coated glass chambers. 
Cardiomyocyte sarcomere function was examined using the Soft 
Edge MyoCam system (IonOptix Corporation), as previously 
described.3,18,20–23 Only myocytes with normal sarcomeric appearance 
(absence of sarcomeric blebs) were used in these experiments. Peak 
shortening (sarcomere BL% peak height; cellular equivalent of %FS), 
time to 90 percent of peak shortening (TPS90), time to 90 percent 
relengthening (TR 90), and velocities of shortening (-dL/dt) and 
relengthening (+dL/dt) were measured following stimulation at 1 Hz. 
Assessment of Cardiomyocyte Calcium Signaling 
Ca2+ transients and caffeine-induced Ca2+ release were 
measured in isolated myocytes loaded with fura-2 AM, as previously 
described.3,18,20–23 Briefly, myocytes were incubated with 0.5 μM fura-2 
AM for 10 minutes and fluorescence was recorded using the Ionoptix 
dual-excitation fluorescence photomultiplier system through a 40x oil 
immersion objective. Fluorescence was achieved by excitation at 360 
nm, followed by 380 nm, and emission was detected between 480–520 
nm. For Ca2+ transient measurements, cells were stimulated at 0.5 Hz 
and changes in cytosolic Ca2+ levels were inferred from the ratio of 
fluorescence intensity at the two wavelengths. Caffeine-induced Ca2+ 
release from the SR was assessed in fura-2AM loaded cells by rapidly 
applying 20 mM caffeine and recording the resulting transient. 
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Integration under the resulting caffeine-induced Ca2+ release curve 
was calculated as an index of SR Ca2+ concentration. 
Calcium sparks were measured by loading isolated 
cardiomyocytes with 20 μM Fluo-3 AM and 5% pluronic acid in 
Tyrode’s Solution, which contained, in mM: 140 NaCl, 4 KCl,, 2 CaCl2, 
1 MgCl2, 10 glucose, and 10 HEPES; pH 7.4 with NaOH. Cells were 
imaged using an inverted Zeiss 710 confocal microscope.24 
GSSG/GSH Assay 
The ratio of oxidized-to-reduced glutathione (GSSG/GSH) in left 
ventricular homogenates in all groups was measured as previously 
described,25 as a global measure of antioxidant status in the heart. 
Blood Pressure Measurements 
Blood pressures were measured at baseline (prior to 
tumor/control injection), 12, and 18 days post injection using a 
computerized tail cuff system (BP-2000 Series II Visitech System Inc., 
Apex, North Carolina) as described previously.18 Mice were trained 
before the procedure for 5 consecutive days to avoid anxiety during 
the procedure. In order to minimize procedure-induced effects, 
measurements were separated by 20 seconds to restore blood flow 
through the tail and preliminary assessments were not used for 
analyses. Ten values were recorded and averaged for analyses of the 
data from each mouse. 
Angiotensin II Immunoassay 
Blood was collected 18 days following tumor cell or sham 
injection and the serum was separated using Microtainer Serum 
Separator Tubes (BD, Franklin Lakes, NJ). Angiotensin II 
concentrations were assessed using a Fluorescent Immunoassay 
(Phoenix Pharmaceuticals, Inc. Burlingame, CA). According to the 
manufacturer’s instructions, serum and primary antibody were 
incubated on a pre-coated fluorescent plate at 4°C overnight. 
Subsequently, a biotinylated Angiotensin-II peptide was added and 
allowed to incubate for 1.5 hours at room temperature. After washing, 
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samples were incubated with a Streptavidin-horseradish peroxidase 
conjugate (SA-HRP) for 1 hour at room temperature before the 
substrate was added and the reaction proceeded for 20 minutes before 
the relative fluorescence was determined using a fluorescent plate 
reader at an excitation and emission maxima of 325 and 420 nm 
respectively. Results were obtained by comparing the optical density 
to a standard series using 4-parameter logistic curve fitting software. 
Colon26 (c26) Adenocarcinoma Cell Proliferation Assay 
The effects of Losartan on c26 Adenocarcinoma cell proliferation 
were determined using a Tryptan blue assay. Cells were seeded at the 
same density onto separate plates and allowed to adhere overnight. 
The following day, either 1 mM or 10 mM of Losartan was added to the 
cells as previously described.26 Once the control cells reached 
confluence, the media was removed and the cells were trypsinized, 
centrifuged and re-suspended in DPBS. Cells were mixed together with 
Trypan blue and viable cells were counted on an Improved Neubauer 
Hemocytometer and expressed as cells/mL. 
Statistical Analyses 
Data were analyzed using a two-way ANOVA to uncover main 
effects of tumor and drug treatment and interaction effect of tumor 
and drug treatment on outcome measures, followed by Bonferroni 
post-hoc testing to uncover specific group differences. For blood 
pressure measurements, the mean of five measures was used for 
statistical analyses. Statistical significance was set at p<0.05. Data are 
reported as mean ± standard error of the mean (SEM). 
Results 
Losartan treatment prevented tumor-related muscle 
wasting and reduced tumor progression 
Body weights, excluding tumor weights, were assessed on day 
19 and not different between tumor/sham and control/sham or 
tumor/LOS and control/LOS treated mice. However, tumor/LOS 
treated mice had lower body weights compared to control/sham 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Molecular and Cellular Cardiology, Vol 85 (August 2015): pg. 37-47. DOI. This article is © Elsevier and 
permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission 
for this article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
10 
 
treated mice and statistical analyses indicated that Losartan treatment 
had a significant effect (p<0.05) on body weight (Table 1). Relative 
gastrocnemius weights were significantly lower in tumor/sham mice 
compared to control/sham mice. However, gastrocnemius weights 
were not different between tumor/LOS and control/LOS treated mice. 
Statistical analyses indicated that tumor cell injection significantly 
reduced gastrocnemius muscle weight relative to body weight 
(p<0.05), with no effect of Losartan treatment (p=.06) on relative 
gastrocnemius weights (Table 1). These data suggest that Losartan 
mitigated muscle wasting in the tumor-bearing mice. Heart weights 
were not different between groups and neither tumor growth nor 
Losartan treatment had an effect on relative heart weight (Table 1). 
Tumor weights were significantly lower in tumor/LOS mice compared 
to tumor mice (p=.01), suggesting that Losartan treatment 
significantly reduced tumor growth. 
Table 1. Normalized body weight (exclusive of tumor weight), heart weight, 
gastrocnemius weight and tumor weight in mice. Normalized gastrocnemius 
and heart weight was calculated by dividing the measured tissue weight by 
the body weight. Data were analyzed using two-way ANOVA (tumor growth, 
Losartan treatment) and Bonferroni post hoc tests. Tumor weights were 
analyzed using student’s t test. 
 
 Body 
weight 
(excl. 
tumor 
weight) 
(g) 
Gastrocnemius 
weight (rel.) 
(mg/g) 
Gastrocnemius 
weight (abs.) (g) 
Heart 
weight 
(rel.) 
(mg/g) 
Heart 
weight 
(abs.) 
(mg) 
Tumor 
weight (g) 
control/sham 
(n=25) 
21.4±0.4 4.76±0.2 9.88±0.24 6.27±0.27 133±2 N/A 
tumor/sham 
(n=26) 
19.6±0.4 4.22±0.2* 7.85±0.34* 6.87±0.37 132±2 1.26±0.1 
control/LOS 
(n=20) 
20.7±0.4 4.89±0.6 9.69±0.37 6.22±0.3 128±2 N/A 
tumor/LOS 
(n=17) 
18.4±0.6* 4.91±0.2 8,36±0.27* 6.63±0.5 118±2 0.88±0.1* 
*p<0.05 compared to respective control. 
Tumor-related cardiac degradation and inflammation is 
attenuated by Losartan treatment 
Cardiac MAFbx, Bnip3, and IL-6 mRNA expression were 
significantly increased in tumor/sham compared to control/sham mice. 
However, cardiac MAFbx and Bnip3 mRNA expressions were not 
increased in tumor/LOS treated mice compared to control/LOS and 
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control/sham treated mice. IL-6 expression was not significantly 
different in tumor/LOS compared to control/LOS mice, but it was 
significantly lower than in tumor/control mice. Statistical analyses 
indicated effects of tumor cell injection on cardiac MAFbx (p<.001), 
Bnip3 (p=.01), and IL-6 (p<.001) mRNA expression. Losartan 
treatment had a significant effect on IL-6 mRNA expression (p<.05) 
alone, indicating that Losartan reduced expression of IL-6 mRNA in the 
hearts of both tumor-bearing and control mice (Figures 1A–C). 
 
Figure 1. Gene expression of MAFbx (A), Bnip3 (B) and IL-6 (C) in cardiac tissue of 
tumor-bearing and Losartan-treated mice. Gene expression levels were determined 
using RT-PCR and are normalized to GAPDH expression. A, MAFbx, an indicator of 
ubiquitin proteasome function; B, Bnip3, an indicator of cellular autophagy; C, IL-6, an 
inflammatory cytokine. Data were analyzed using two-way ANOVA and Bonferroni post 
hoc pairwise comparisons. * p<0.05 compared to respective control. n=6 
control/sham, n=5 tumor/sham, n=6 control/LOS, n=7 tumor/LOS. 
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Losartan treatment attenuated tumor-associated 
increases in plasma cytokine levels 
IL-6 and CXCL1 protein concentrations were significantly 
increased in tumor/sham and tumor/LOS compared to respective 
controls (Figures 2A&B). IL-10 protein concentrations were increased 
in tumor/sham compared to control/sham but not in tumor/LOS 
compared to control/LOS treated mice (Figure 2C). Statistical analyses 
revealed an effect of tumor cell injection on plasma levels of IL-6 
(p<.0001), CXCL1 (0.0001), IL-10 (p<0.01), and IL1-β (p<0.05) 
(Figures 2A–D) and an effect of Losartan treatment on plasma TNF-α 
levels (p<0.05) (Figure 2E). Neither tumor cell injection nor Losartan 
treatment affected plasma levels of IFN-γ (Figure 2F). 
 
Figure 2. Plasma pro-inflammatory cytokine levels in tumor-bearing and Losartan-
treated mice. Cytokine levels were determined using the Pro-inflammatory 7-Plex 
Ultra-Sensitive Kit. Data were analyzed using two-way ANOVA (tumor growth and 
Losartan treatment) and Bonferroni post hoc pairwise comparisons. * p<0.05 
compared to respective control, n=10. 
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Losartan treatment prevented tumor-associated 
changes in LV dimensions and preserved myocardial 
function 
Tumor cell injection reduced fractional shortening (FS), ejection 
fraction (EF), stroke volume (SV), posterior wall thickness in diastole 
(PWTd), and systole (PWTs) and increased systolic left ventricular 
dimension (LVEDs) in tumor/sham mice compared to control/sham 
mice. Losartan treatment prevented tumor-associated alterations in 
left ventricular dimensions and function. EF, EF, SV, PWTd, PWTs, were 
significantly greater and LVEDd, and LVEDs significantly lower in 
tumor/LOS treated mice compared to tumor/sham mice. There were 
no differences between control/LOS and tumor/LOS treated mice. 
Heart rates were not different between groups. Statistical analyses 
indicated effects of tumor cell injection, Losartan treatment, and an 
interaction effect on LVEDs (p<0.001), PWTs (p<0.05), SV (p<0.01), 
EF (p<0.0001), and FS(p<0.0001) (Table 2). These results indicate 
that tumor cell injection reduced cardiac wall diameter and myocardial 
contractility, with Losartan treatment mitigating the effects of tumor 
cell injection on cardiac diameter and myocardial function. 
Table 2. In vivo echocardiographic parameters in tumor-bearing and 
Losartan-treated mice. Fractional shortening (FS), ejection fraction (EF), left 
ventricular end diastolic diameter (LVEDd), left ventricular end systolic 
diameter (LVESd), posterior wall thickness during diastole (PWTd), posterior 
wall thickness during systole (PWTs) and stroke volume (SV) in tumor-bearing 
and LOS-treated animals. Values were calculated from m-mode 
electrocardiograms as shown in Figure 3. Data were analyzed using two-way 
ANOVA (tumor growth and Losartan treatment) and Bonferroni post hoc tests. 
 
 control/sham (n=15) tumor/sham (n=17) control/LOS (n=14) tumor/LOS (n=10) 
FS (%) 37.6±1.1 23.0±0.85* 38.5±0.9# 35.9±0.5# 
EF 68.2±1.4 46.4±1.4* 68.8±1.1# 66.0±0.8# 
LVEDd (mm) 3.87±0.1 4.18±0.1 3.96±1.9 3.98±0.1 
LVEDs (mm) 2.45±0.1 3.21±0.1* 2.47±0.1# 2.55±0.1# 
PWTd (mm) 0.77±0.3 0.63±0.01* 0.74±0.03# 0.71±0.03 
PWTs (mm) 1.10±0.04 0.88±0.02* 1.14±0.03# 1.06±0.03# 
SV (μl) 35.0±1.9 24.4±0.8* 36.0±1.7# 38.9±1.5# 
HR (BPM) 455±11 460±12 449±8 442±9 
LV mass (mg) 93.25±5.48 83.80±2.94 104.08±7.91 93.10±5.67 
*p<0.05 compared to respective control, 
#p<0.05 compared to tumor/sham. 
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Furthermore, there was an effect of tumor cell injection 
(p<.001) and an interaction effect (p<0.05) of tumor cell injection and 
Losartan treatment on PWTd.; post hoc analyses revealed no 
significant differences between tumor/LOS and either group of control 
mice, suggesting that Losartan mitigated the effects of tumor cell 
injection. However, neither tumor cell injection nor Losartan treatment 
affected LVEDd (Figure 3, Table 2). 
 
Figure 3. Representative M-mode in vivo echocardiographic images obtained at the 
mid-papillary muscle level of tumor-bearing and Losartan-treated mice. Images 
include electrocardiogram and respiratory traces at the bottom. 
Tumor-induced cardiomyocyte dysfunction is improved 
with Losartan treatment 
Percent sarcomeric peak shortening (%PS, the cellular 
equivalent of in vivo fractional shortening) (Figure 4A) was not 
affected by either tumor cell injection or Losartan treatment. However, 
time-to-90% peak shortening (TPS90) and time-to-90 percent 
relengthening (TR90) were significantly increased in tumor/sham 
compared to control/sham treated mice and further increased in 
tumor/LOS compared to tumor/sham treated mice. Statistical analyses 
indicated effects of tumor cell injection on TPS90 (p<.0001) and TR90 
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(p<0.05), and effects of Losartan treatment on TPS90 (p<.001) and 
TR90 (p<0.05). These data suggest that the effects of Losartan 
treatment on peak shortening and relengthening were independent of 
the tumor condition and could be related to the tendency of Losartan 
to cause hypertrophy.27,28 
 
Figure 4. In vivo myocyte function in tumor-bearing and Losartan-treated mice. A, 
percent peak sarcomere shortening (Sarcomere BL). B, time to 90 percent of peak 
shortening (TPS90). C, time to 90 percent relengthening (TR90). D, velocity of 
myocyte shortening. E, velocity of myocyte relengthening. Data were analyzed using 
two-way ANOVA (tumor growth and Losartan treatment) and Bonferroni post hoc 
pairwise comparisons. * p<0.05 compared to respective control. Myocyte cell 
numbers: n=70 cells/12 mice control/sham, n=97 cells/17 mice tumor/sham, n=45 
cells/4 mice control/LOS, n=61 cells/8 mice tumor/LOS. 
In contrast, depolarization velocity (-dL/dt) was increased in 
tumor/sham compared to control/sham and tumor/LOS treated mice. 
Statistical analyses indicated an effect of Losartan treatment 
(p<0.001) and an interaction between tumor cell injection and 
Losartan treatment (p<0.005) on -dL/dt. The velocity of relengthening 
(+dL/dt) was significantly increased in tumor/sham compared to 
tumor/LOS mice. Statistical analyses indicated an interaction of tumor 
cell injection and Losartan treatment on +dL/dt (p<0.01) (Figures 4D 
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& E). These findings suggest an effect of Losartan on the mechanics of 
sarcomeric function that requires further mechanistic investigation. 
Losartan treatment attenuated tumor-induced changes 
in calcium signaling 
Calcium transient amplitude and calcium reuptake velocity were 
increased in tumor/sham compared to control/sham and tumor/LOS 
mice. Furthermore, calcium transient amplitude was increased in 
tumor/LOS but maximum velocity of calcium transients was not 
different compared to control/LOS treated mice. Statistical analyses 
revealed effects of tumor cell injection and Losartan treatment on 
calcium transient amplitude (p<.001), and an additional interaction 
effect of tumor cell injection and Losartan treatment on calcium 
reuptake velocity (p<.001) (Figure 5A–B). These effects on calcium 
transients and reuptake suggest that Losartan treatment normalized 
calcium currents in the myocytes of tumor-bearing mice. 
 
Figure 5. Cardiomyocyte calcium signaling in tumor-bearing and Losartan-treated mice. A, amplitude of 
stimulated Ca2+ transients. B, amplitude of calcium sparks. C, amplitude of caffeine induced Ca2+ release. D, 
Integration under the caffeine-induced Ca2+ release curve as an index of SR Ca2+ concentration. Data 
analyzed using two-way ANOVA (tumor growth, Losartan treatment), followed by Bonferroni post hoc 
pairwise comparisons. * p<0.05 compared to respective control. Myocyte cell numbers for calcium analysis: 
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n=27 cells/11 mice control/sham, n=40 cells/14 mice tumor/sham, n=29 cells/4 mice control/LOS, n=52 
cells/8 mice tumor/LOS. 
Spark amplitude was lower in control/LOS compared to 
control/sham treated mice. Statistical analyses indicated an effect of 
Losartan on spark amplitude (p<0.01) (Figure 5C). Caffeine-induced 
calcium release was increased in tumor/LOS compared to control/LOS 
and tumor/sham treated mice. Statistical analyses indicated an effect 
of tumor cell injection on caffeine induced calcium release (p<0.005) 
(Figure 5D). 
GSH/GSSG levels are increased in hearts of tumor-
bearing mice 
Left ventricular GSH/GSSG levels were not different between 
groups; however, statistical analysis indicated an effect of tumor cell 
injection (p<0.05) on the GSH/GSSG ratio (Figure 6). 
 
Figure 6. Oxidative stress in ventricular tissue of tumor-bearing and Losartan-treated 
mice. The ratio of GSH/GSSG was used to approximate oxidative stress in left 
ventricular tissue. Data analyzed using two-way ANOVA (tumor growth, Losartan 
treatment), followed by Bonferroni post hoc pairwise comparisons. No significance was 
observed with Losartan treatment. n=5. 
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Tumor growth and Losartan treatment affected blood 
pressure 
Systolic blood pressure was lower in control/LOS compared to 
control/sham treated mice 12 days after tumor cell injection (data not 
shown). Statistical analyses indicated effects of Losartan treatment 
(p<0.05) and an interaction between Losartan treatment and tumor 
cell injection (p<0.05) on systolic blood pressure. Diastolic blood 
pressures and developed pressures were not different between groups 
12 days after tumor cell injection and/or Losartan treatment. However, 
18 days post tumor cell injection systolic and developed pressures 
were significantly lower in tumor/sham compared to control/sham 
mice. However, there was no difference in tumor/LOS treated mice 
compared to control/sham or control/LOS treated mice. Statistical 
analyses indicated interaction effects of tumor cell injection and 
Losartan treatment on systolic (p<0.05) and developed (p<0.001) 
blood pressures. Furthermore, diastolic blood pressures were lower in 
control/LOS and tumor/LOS treated mice compared to respective 
control/sham and tumor/LOS treated mice. Statistical analyses 
indicated an effect of Losartan treatment on diastolic blood pressure 
(P<0.05) (Table 3). 
Table 3. Blood pressure in tumor-bearing and Losartan-treated mice. Systolic 
blood pressure, diastolic blood pressure and developed pressure on days 12 
and 18. days after tumor cell injection. Data were analyzed using two-way 
ANOVA (tumor growth and Losartan treatment) and Bonferroni post hoc tests. 
 
 control/sham 
(n=4) 
tumor/sham 
(n=4) 
control/LOS 
(n=5) 
tumor/LOS 
(n=5) 
D12 Systolic blood 
pressure (mmHg) 
120±1 106±2 103±4 107±4 
D12 Diastolic blood 
pressure (mmHg) 
46±4 53±5 46±4 53±10 
D12 developed pressure 
(mmHg) 
74±3 54±6 58±6 55±10 
D18 Systolic blood 
pressure (mmHg) 
125±4 99±3* 103±3 109±9 
D18 Diastolic blood 
pressure (mmHg) 
58±4 59±7 41±3 41±2 
D18 developed pressure 
(mmHg) 
68±7 40±6* 61±2 68±7 
*p<0.05 compared to respective control. 
  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Molecular and Cellular Cardiology, Vol 85 (August 2015): pg. 37-47. DOI. This article is © Elsevier and 
permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission 
for this article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
19 
 
Tumor cell injection increased Angiotensin II serum levels 
Angiotensin II serum levels from tumor/control and tumor/LOS treated 
mice were increased compared to sham/control and sham/LOS treated 
mice, respectively. Statistical analyses indicated a significant effect of 
tumor cell injection on Angiotensin II serum levels (Figure 7). 
 
Figure 7. Angiotensin II Protein levels in mouse serum of tumor-bearing and Losartan 
treated mice 18 days after tumor cell or sham injection. Data were analyzed using 
two-way ANOVA (tumor growth, Losartan treatment), followed by Bonferroni post hoc 
pairwise comparisons. * p<0.01 compared to control, n=4. 
Inhibitory effects of Losartan on c26 Adenocarcinoma 
cell proliferation 
Losartan treatment significantly inhibited the proliferation of c26 
adenocarcinoma cells in vitro compared to non-Losartan treated 
control cells (p<0.001) (Figure 8). 
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Figure 8. Effects of Losartan on c26 Adenocarcinoma cell proliferation. Cells were 
cultured with 1 mM/L, 10 mM/L or without Losartan for 3 days. Data were analyzed 
using one-way ANOVA. Losartan significantly inhibited the proliferation of c26 
Adenocarcinoma cell at both concentrations. p<0.001, n=6. 
Discussion 
As shown in Table 1, treatment with Losartan preserved 
gastrocnemius muscle mass in c26 tumor-bearing mice, without 
improving body weight. The RAAS affects fatty acid and glucose 
metabolism and ACE deficiency, resulting in a reduction in body 
weight.29 Based on these data, we speculate that the observed 
reduction in body weight of tumor-bearing and Losartan treated mice 
could be related to Losartan-induced alterations of the RAAS and 
subsequent effects on glucose and fatty acid metabolism. Tumor 
bearing and Losartan treatment had no significant effects on heart 
weight normalized to body weight. Based on the results of others, 
however, it is likely that heart mass may have decreased had the 
tumor-bearing mice been allowed to develop more severe cachexia 
prior to euthanasia and the presented results are not due to cachexia 
but tumor presence.5 
Echocardiographic studies confirmed our earlier findings of 
systolic dysfunction in c26 tumor-bearing mice3 (Table 2). This 
dysfunction was attenuated by treatment with Losartan. These data 
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are in accordance with others that investigated in liver cancer induced 
cardiac failure and reported an attenuation of tumor induced left 
ventricular dysfunction in beta blocker and mineralocorticoid receptor 
antagonist treated mice.10 Our data suggest that Losartan may be 
useful in preserving myocardial function in patients with cancer 
associated cardiac dysfunction. 
Tumor cell injection prolonged contraction and depolarization 
velocities of isolated cardiomyocytes. At the cellular level, tumor 
progression prolonged TPS90 and TR90 in isolated cardiomyocytes. 
However, Losartan treatment also prolonged TPS90 and TR90 in 
myocytes from tumor and control mice, such that there were no longer 
any differences between the myocytes of tumor and control mice 
(Figures 4B and 4C). These data suggest that other non-myocyte cell 
types could play a role in normalization of myocardial function in the 
tumor-bearing mice, such as activation of proteins involved in the 
production of the extracellular matrix. Other possible explanations for 
the improvements in in vivo cardiac function, but not in vitro cellular 
parameters, include myocyte apoptosis or a change in intracellular 
communication. 
We also examined the direct effects of Losartan treatment on 
blood pressure. Our results show a reduction of systolic blood pressure 
and developed pressure, representing the circulatory consequences 
and confirming the reported in vitro and in vivo results indicating 
myocardial dysfunction 18 days following tumor cell injection. 
Distinctly, Losartan affected blood pressure in the presence as well as 
the absence of tumor, suggesting direct effects of Losartan on blood 
pressure. The reduction in blood pressure indicates a direct effect of 
Losartan on the circulation (Table 3). 
It is clear that Losartan improved myocardial function in this 
mouse model of cancer cachexia and there are several plausible 
mechanisms. Our data indicate that Losartan altered pro-inflammatory 
activity as observed by a decrease in IL-6 mRNA expression in the 
heart, which is thought to be a key step in activation of the UPP of 
myosin degradation.30 Activation of the UPP is a known effect of 
AngII16 and pro-inflammatory cytokines, such as IL-1, IL-6, and TNF-α 
induced NF-κB activation have been reported to be the mechanisms of 
altered striated muscle mass in tumor-bearing cancer models,31 thus it 
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is not surprising that Losartan treatment would preserve 
gastrocnemius muscle mass in tumor-bearing mice (Table 1). 
Losartan treatment affected Ca2+ transient amplitude in 
cardiomyocytes from both the control and tumor groups (Figure 5A), 
but affected the area under the Ca2+ release curve (Figure 5D), which 
is an index of SR Ca2+ levels, in only the tumor-bearing mice. The 
change in the caffeine-induced Ca2+ release curve was potentially due 
to Losartan increasing the expression of NCX,32 which is the sole 
channel responsible for clearing Ca2+ from the cytosol during 
treatment with caffeine. It is, however, unlikely that Ca2+ signaling is 
the entire mechanism of improvement following Losartan treatment as 
tumor-induced changes in the amplitude of the Ca2+ transient are 
unaffected by Losartan. However, these data require further 
investigation. 
The increase in the relative amount of MHC-β is consistent with 
an earlier report5 from a study using the same tumor-bearing model. 
The increased amount of MHC-β in the tumor-bearing mice likely 
contributed to the observed prolonged time to peak shortening in 
isolated myocytes. Even small differences in the MHC isoform 
composition of isolated cardiomyocytes can affect power output, with 
an increase in the amount of MHC-β being associated with reduced 
power.33–35 However, an increase in the amount of MHC-β is associated 
with increased economy of myocardial contraction,36 potentially 
providing a beneficial adaptation in the tumor-bearing mice, which 
eventually develop a reduction in cardiac wall thickness.2 The increase 
in the amount of MHC-β was also associated with an increase in the 
amount of one of the apparent MHC-α fragments (MHC-α′) in tumor-
bearing, which could also be an adaptation to maintain force 
generating ability with increased economy. Interestingly, increased 
MHC breakdown has also been reported in skeletal muscle with the 
same tumor-bearing mouse model.37 
The relative amount of MHC-β was not different between 
control/LOS and tumor/LOS mice. This is consistent with Losartan 
reversing the increase in the mRNA and protein levels of MHC-β 
following induced heart failure in rats.38–40 There was an increase in 
the relative amount of apparent MHC-α proteolytic fragments in 
Losartan-treated mice. The responsible mechanism is not known, but it 
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is possible that there is increased proteolytic activity associated with 
changes in MHC expression and replacement in myofibrils during 
Losartan treatment. 
Ca2+ transient amplitude was altered in tumor/LOS mice (Figure 
5A), with no change in cardiomyocyte peak shortening (Figure 4A). 
This suggests that there could have been a change in myofilament 
Ca2+ sensitivity, which is often observed during ventricular 
hypertrophy.41 This would also be a potential explanation for the 
decrease in myocardial function in the tumor-bearing mice. 
AngII is known to increase ROS production in various 
diseases.42–44 AngII causes the formation of reactive oxygen species in 
vivo, mediated by AT2 in response to hypertension. Thus, we also 
examined the GSH/GSSG ratios as a marker for the presence of 
oxidative stress in heart tissue as a potential mechanism of myocardial 
dysfunction observed in tumor-bearing mice. While tumor presence did 
increase overall GSH/GSSG levels in heart tissue, Losartan treatment 
surprisingly had no effect on production of this particular marker of 
oxidative stress (Figure 6). AngII receptor blockers have been shown 
to reduce the production of ROS in the kidneys in a mouse model of 
hypertension-induced cardiomyopathy. Based on these reports, our 
data suggest that the observed improvement of cardiac function could 
be related to the direct effects of other reactive oxygen species or 
hormone related improvement in blood pressure. AngII is not likely to 
be involved in the direct cardiac mechanism of action for Losartan-
mediated improvements in myocardial function in tumor-bearing mice. 
Losartan is a selective AT1 receptor antagonist without serious 
adverse effects that is commonly used for the treatment of 
hypertension. In our model Losartan treatment reduced diastolic blood 
pressure in control and tumor mice, but prevented tumor associated 
reduction in systolic blood pressure and most importantly developed 
pressure. 
Accumulating evidence supports the notation that the RAAS 
directly impacts tumor progression through tumor cell proliferation and 
tumor angiogenesis. Furthermore, Losartan has been shown to 
improve the effects of chemotherapeutics, potentially through an 
enhancement of drug delivery in breast and pancreatic cancer 
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models.45 Therefore, another plausible explanation for the observed 
Losartan associated prevention of tumor-associated development of 
cardiac dysfunction could be linked to direct effects of Losartan on 
tumor cells and the tumor itself. However, the direct impact of 
Losartan on adenocarcinoma cell proliferation has not been 
investigated. Thus, we examined the effects of Losartan on c26 
adenocarcinoma cells proliferation and tumor progression. Our data 
indicated that Losartan treatment impaired c26 adenocarcinoma cell 
proliferation in vitro and reduced tumor weight in vivo. In summary, 
our in vitro data indicate a direct effect of Losartan on tumor cells, 
reducing c26 tumor cell proliferation. Antagonizing the AT1 receptor by 
Losartan treatment could be a potential mechanism for the herein 
reported reduction in tumor progression and subsequent prevention of 
tumor associated development of cardiac dysfunction. 
Taken together, our data indicate that Losartan treatment 
impaired c26 adenocarcinoma cell proliferation in vitro, reduced tumor 
weight in vivo, prevented the expression of in cardiac degeneration 
and inflammation involved mediators and attenuated the development 
of tumor-associated cardiac dysfunction in vivo and in vitro. Losartan 
has been shown to reduce VEGF concentrations in various models, 
which subsequently impairs vascular formation in neoplastic tissue 
affecting tumor presence. In our c26 adenocarcinoma model Losartan 
treatment reduced tumor weight and improved tumor induced cardiac 
dysfunction and our in vitro data suggest, that the reduction in tumor 
weight may be due to Losartan induced reduction in c26 
adenocarcinoma cell proliferation. However, one limitation of our study 
is that the presented data do not indicate if the beneficial effects of 
Losartan on tumor-induced cardiac dysfunction are based on direct 
effects of Losartan on tumor cells or the prevention of tumor 
progression and secondary to the heart. Hence, we cannot rule out 
primary effects of Losartan to the heart that directly prevent the 
development of tumor-induced cardiac dysfunction. 
Our herein presented results provide promising new insights into 
the potential role for Losartan, a widely used AT1 receptor antagonist 
that has no serious side effects, for the treatment of tumor-induced 
myocardial dysfunction in cancer patients. 
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Highlights 
 Losartan treatment has a beneficial effect on tumor-mediated cardiac 
dysfunction. 
 Reactive oxygen species are a key component of cancer-mediated 
cardiac dysfunction. 
 Treatment with Losartan affects tumor cell growth in vitro. 
Supplementary Material 
Material and Methods 
Assessment of MHC Isoform Composition. Left ventricular 
homogenates were prepared from the hearts of control and c26 tumor-
bearing mice, as in Reiser and Kline [1]. Myosin heavy chain (MHC) isoform 
composition of left ventricular homogenates was examined using SDS-PAGE 
and scanning densitometry. Gels were also run for mass spectrometry and 
immunoblotting. Separating gels consisted of 7% acrylamide, with a 50:1 
acrylamide:bis-acrylamide crosslinking ratio, and 5% (v/v) glycerol. 
Additional details for the separating and stacking gels were as described in 
Reiser and Kline [1]. The gels were run for 21 hours at 8ºC and 230 constant 
volts. Silver-staining and scanning of the gels were as described previously 
[1, 2], except that the gels were scanned before drying. One gel was stained 
with Coomassie Blue and bands were excised and analyzed with liquid 
chromatography, coupled to tandem mass spectrometry, in the Campus 
Chemical Instrument Center at The Ohio State University [3]. Another gel was 
used for immunoblotting that was probed with an MF 20 antibody, which 
recognizes all sarcomeric MHC isoforms (supernatant from the Developmental 
Studies Hybridoma Bank was diluted to 1:50). Protein bands were detected 
with a secondary antibody conjugated with alkaline phosphatase, as 
previously described [4]. 
Results 
Changes in MHC Isoforms: The amounts of MHC- and MHC- were 
determined by densitometry of silver-stained gels (example shown in panel A 
of Figure S1). There was a small, but significantly (P<0.005) greater amount 
of MHC-, relative to the total amount of MHC, in the left ventricle of tumor-
bearing mice, compared to control mice. There was no difference in the 
relative amount of MHC- between control/LOS and tumor/LOS mice. Several 
protein bands, with electrophoretic mobilities that were greater than that of 
MHC isoforms, were observed on the same gel. An immunoblot with an 
antibody that recognizes all sarcomeric MHC isoforms (MF 20, supernatant, 
diluted 1:50, Developmental studies Hybridoma Bank, University of Iowa, 
Iowa City, IA) was run and three prominent bands were detected, 
corresponding to MHC-, MHC- and a band with greater mobility (panel C of 
Figure S1). The latter band and another band, with even greater mobility and 
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which was not suffucently abundant to be detected by the antibody but was 
visible on stained gels, were excised from a Coomassie-stained gel. These 
bands were submitted for analysis by mass spectrometry in the Ohio State 
University Campus Chemical Instrument Center. 
The six peptides from the digestion of both excised bands that had the 
strongest matches with MHC- were the same for both bands. The MOWSE 
scores from mass spectrometry were 8227 and 2975 for MHC-’ and MHC-’’, 
respectively. These scores far exceed the score (i.e., 53) that is associated 
with a significant probability of correct identification. Given the high MOWSE 
scores, we conclude that these bands are likely to be proteolytic fragments of 
MHC- and are labeled as MHC-’ and MHC-’’. The relative amounts of MHC-
’ and MHC-’’ were individually quantitated relative to the total MHC- pool 
(i.e., the sum of MHC + MHC-’ + MHC-’’) in each sample. The relative 
amount of MHC-’ was significantly greater in tumor-bearing mice, compared 
to control mice, both with and without Losartan treatment. Losartan 
treatment did not affect the relative amount of MHC-’ in control mice, but 
the relative amount of MHC-’ was greater in tumor-bearing mice that were 
treated with Losartan, compared to untreated tumor-bearing mice. There was 
no difference in the relative amount of MHC-’’ between untreated control and 
tumor-bearing groups. Losartan treatment was associated with an increase in 
the relative amount of MHC-’’ in control mice, but not in tumor-bearing mice. 
Figure 
 
 
 
 
 
 
 
 
 
 
Figure. S1. Cardiac myosin heavy chain (MHC) isoforms and proteolytic fragments in control and 
tumor-bearing mice. The MHC region of an SDS gel loaded with left ventricular samples from 
control and tumor-bearing mice, with or without Losartan treatments. B, quantitation of the 
amount of MHC-, relative to total intact MHC (MHC- + MHC-), from scanning densitometry of 
silver-stained gels and quantitation of the amounts of two proteolytic fragments of MHC- (MHC-
α’ and MHC-α”), relative to the total MHC- pool (MHC- + MHC-’ + MHC-’’), from scanning 
densitometry of silver-stained gels. * p<0.05 compared to respective control (n=6). 
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